Atopic dermatitis and inflammatory skin diseaseTreatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Key words
Abbreviations used
Cited by (0)
The funder of the study, MedImmune, a member of the AstraZeneca Group, contributed to the study design, collection, analysis, and interpretation of the data and funding of medical writing and editorial support for the report. All authors had full access to all data, and the corresponding author had final responsibility for the decision to submit for publication.
Disclosure of potential conflict of interest: A. Wollenberg has received grants or personal fees from Almirall, Anacor, Astellas, Beiersdorf, Bioderma, Celgene, Chugai, Galderma, GlaxoSmithKline, Hans Karrer, Leo Pharma, L'Oreal, MEDA, MedImmune, MSD, Novartis, Pierre Fabre, Pfizer, Regeneron, and Sanofi. M. D. Howell was an employee of MedImmune at the time that the original study and this analysis was conducted; he is currently an employee of Incyte Corporation and has a patent relating to DPP-4 and periostin as biomarkers for IL-4α receptor activation in atopic dermatitis. E. Guttman-Yassky has received grants from BMS, Celgene, Dermira, Janssen Biotech, LEO Pharma, Merck Pharmaceuticals, Novartis, and Regeneron and consulting fees or honoraria from AbbVie, Allergan, Amgen, Anacor, BMS, Celgene, Celsus Therapeutics, Dermira, Drais, Eli Lilly, Escalier, Galderma, Genentech, Glenmark, GlaxoSmithKline, LEO Pharma, Mitsubishi Tanabe, Novartis, Pfizer, Regeneron, Sanofi, and Vitae. J. I. Silverberg has received grants or personal fees from AbbVie, Anacor, Galderma, GlaxoSmithKline, Intraderm, Kiniksa, MedImmune, Menlo, Pfizer, and Regeneron-Sanofi. C. Kell is an employee of MedImmune and holds stock in AstraZeneca. K. Ranade is an employee of MedImmune and has a pending patent relating to DPP-4 as a predictive biomarker of tralokinumab efficacy. R. Moate is an employee of MedImmune and hold shares in MedImmune and GlaxoSmithKline. R. van der Merwe is an employee of MedImmune and holds shares in AstraZeneca.
- ∗
Michael D. Howell, PhD, is currently affiliated with Incyte Corporation.